CA1041424A - Isolation des facteurs de coagulation dans des produits biologiques - Google Patents

Isolation des facteurs de coagulation dans des produits biologiques

Info

Publication number: CA1041424A
Authority: CA; Canada
Prior art keywords: factor; fibrinogen; cross; linked; solution
Prior art date: 1974-05-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA199,415A

Other languages

English (en)

Other versions

CA199415S (en

Inventor

Lars-Olov Andersson

Hakan Borg

Elisabeth Ehrenberg

Nanna Forsman

Gunnar Hanshoff

Goran Lindroos

Maggie Miller-Andersson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Phadia AB

Original Assignee

Kabi AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-05-09

Filing date

1974-05-09

Publication date

1978-10-31

1974-05-09 Application filed by Kabi AB filed Critical Kabi AB

1974-05-09 Priority to CA199,415A priority Critical patent/CA1041424A/fr

1978-10-31 Application granted granted Critical

1978-10-31 Publication of CA1041424A publication Critical patent/CA1041424A/fr

Status Expired legal-status Critical Current

Links

102000015081 Blood Coagulation Factors Human genes 0.000 title abstract description 11
108010039209 Blood Coagulation Factors Proteins 0.000 title abstract description 11
239000003114 blood coagulation factor Substances 0.000 title abstract description 11
238000002955 isolation Methods 0.000 title description 6
239000012620 biological material Substances 0.000 title 1
108010049003 Fibrinogen Proteins 0.000 claims abstract description 85
102000008946 Fibrinogen Human genes 0.000 claims abstract description 85
229940012952 fibrinogen Drugs 0.000 claims abstract description 82
238000000034 method Methods 0.000 claims abstract description 69
210000004369 blood Anatomy 0.000 claims abstract description 52
239000008280 blood Substances 0.000 claims abstract description 52
229920002307 Dextran Polymers 0.000 claims abstract description 43
229920000936 Agarose Polymers 0.000 claims abstract description 36
239000011159 matrix material Substances 0.000 claims abstract description 23
241001465754 Metazoa Species 0.000 claims abstract description 14
239000007788 liquid Substances 0.000 claims abstract description 6
239000000499 gel Substances 0.000 claims description 142
239000000243 solution Substances 0.000 claims description 73
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 55
210000002381 plasma Anatomy 0.000 claims description 46
239000000047 product Substances 0.000 claims description 46
229960002086 dextran Drugs 0.000 claims description 40
210000001519 tissue Anatomy 0.000 claims description 38
239000000872 buffer Substances 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 30
239000003795 chemical substances by application Substances 0.000 claims description 28
239000011780 sodium chloride Substances 0.000 claims description 28
229960000633 dextran sulfate Drugs 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
238000010828 elution Methods 0.000 claims description 19
239000002156 adsorbate Substances 0.000 claims description 15
239000001509 sodium citrate Substances 0.000 claims description 15
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 15
239000007864 aqueous solution Substances 0.000 claims description 13
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 11
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
239000007979 citrate buffer Substances 0.000 claims description 10
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 10
229920000669 heparin Polymers 0.000 claims description 10
229960002897 heparin Drugs 0.000 claims description 10
108010035369 Cohn fraction I Proteins 0.000 claims description 9
239000011543 agarose gel Substances 0.000 claims description 9
239000011324 bead Substances 0.000 claims description 9
230000015271 coagulation Effects 0.000 claims description 8
238000005345 coagulation Methods 0.000 claims description 8
239000002244 precipitate Substances 0.000 claims description 8
208000009292 Hemophilia A Diseases 0.000 claims description 7
238000000502 dialysis Methods 0.000 claims description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
208000031220 Hemophilia Diseases 0.000 claims description 6
230000023555 blood coagulation Effects 0.000 claims description 6
238000005119 centrifugation Methods 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
108010054218 Factor VIII Proteins 0.000 claims description 5
102000001690 Factor VIII Human genes 0.000 claims description 5
238000003756 stirring Methods 0.000 claims description 5
239000006228 supernatant Substances 0.000 claims description 5
WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical group NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
239000012062 aqueous buffer Substances 0.000 claims description 3
229940059329 chondroitin sulfate Drugs 0.000 claims description 3
229960000301 factor viii Drugs 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
102100023804 Coagulation factor VII Human genes 0.000 claims description 2
229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims description 2
108010023321 Factor VII Proteins 0.000 claims description 2
239000012153 distilled water Substances 0.000 claims description 2
239000000706 filtrate Substances 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
239000003125 aqueous solvent Substances 0.000 claims 4
229910017053 inorganic salt Inorganic materials 0.000 claims 3
229940024546 aluminum hydroxide gel Drugs 0.000 claims 2
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims 2
239000012736 aqueous medium Substances 0.000 claims 2
239000012475 sodium chloride buffer Substances 0.000 claims 2
MBJAPGAZEWPEFB-UHFFFAOYSA-N 5-amino-2-(4-amino-2-sulfophenyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(N)=CC=C1C1=CC=C(N)C=C1S(O)(=O)=O MBJAPGAZEWPEFB-UHFFFAOYSA-N 0.000 claims 1
239000006096 absorbing agent Substances 0.000 claims 1
239000006172 buffering agent Substances 0.000 claims 1
229940012413 factor vii Drugs 0.000 claims 1
239000007791 liquid phase Substances 0.000 claims 1
230000001376 precipitating effect Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
102100022641 Coagulation factor IX Human genes 0.000 abstract description 37
108010076282 Factor IX Proteins 0.000 abstract description 34
229960004222 factor ix Drugs 0.000 abstract description 31
239000012141 concentrate Substances 0.000 abstract description 27
235000008504 concentrate Nutrition 0.000 abstract description 27
238000001179 sorption measurement Methods 0.000 abstract description 20
239000000463 material Substances 0.000 abstract description 10
229940019700 blood coagulation factors Drugs 0.000 abstract description 7
239000000126 substance Substances 0.000 abstract description 4
150000001720 carbohydrates Chemical class 0.000 abstract description 3
238000001042 affinity chromatography Methods 0.000 abstract description 2
239000010836 blood and blood product Substances 0.000 abstract description 2
229940125691 blood product Drugs 0.000 abstract description 2
229920002684 Sepharose Polymers 0.000 description 40
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 34
235000018102 proteins Nutrition 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
238000002360 preparation method Methods 0.000 description 21
230000000694 effects Effects 0.000 description 20
239000007858 starting material Substances 0.000 description 18
238000013019 agitation Methods 0.000 description 17
229960001790 sodium citrate Drugs 0.000 description 11
235000011083 sodium citrates Nutrition 0.000 description 11
238000005194 fractionation Methods 0.000 description 10
229920005654 Sephadex Polymers 0.000 description 8
239000012507 Sephadex™ Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
208000032843 Hemorrhage Diseases 0.000 description 7
229910000033 sodium borohydride Inorganic materials 0.000 description 7
239000012279 sodium borohydride Substances 0.000 description 7
108010048049 Factor IXa Proteins 0.000 description 6
239000011149 active material Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
230000008901 benefit Effects 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
238000003795 desorption Methods 0.000 description 5
239000004023 fresh frozen plasma Substances 0.000 description 5
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
230000008569 process Effects 0.000 description 5
238000005406 washing Methods 0.000 description 5
229920002567 Chondroitin Polymers 0.000 description 4
208000034158 bleeding Diseases 0.000 description 4
231100000319 bleeding Toxicity 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 4
239000012847 fine chemical Substances 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
JCUYNPHEESTECG-UHFFFAOYSA-N 3-amino-6-(4-aminophenyl)benzene-1,2-disulfonic acid Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C(S(O)(=O)=O)=C1S(O)(=O)=O JCUYNPHEESTECG-UHFFFAOYSA-N 0.000 description 3
241000220317 Rosa Species 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229940105774 coagulation factor ix Drugs 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
208000009429 hemophilia B Diseases 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
229940105778 coagulation factor viii Drugs 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
208000031169 hemorrhagic disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000011259 mixed solution Substances 0.000 description 2
JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
VAANUEHPYNAMQR-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)cyclohexa-2,4-diene-1,1-disulfonic acid Chemical compound OS(=O)(=O)C1(S(O)(=O)=O)CC(N)=CC=C1C1=CC=C(N)C=C1 VAANUEHPYNAMQR-UHFFFAOYSA-N 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241001146702 Candidatus Entotheonella factor Species 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
229940122036 Factor XIa inhibitor Drugs 0.000 description 1
229940123583 Factor Xa inhibitor Drugs 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
229940105772 coagulation factor vii Drugs 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
-1 cyano- Chemical class 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000009429 distress Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000000727 fraction Substances 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
229910001679 gibbsite Inorganic materials 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000002085 hemarthrosis Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000001459 mortal effect Effects 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
229940070376 protein Drugs 0.000 description 1
108010012557 prothrombin complex concentrates Proteins 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000002226 simultaneous effect Effects 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA199,415A 1974-05-09 1974-05-09 Isolation des facteurs de coagulation dans des produits biologiques Expired CA1041424A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA199,415A CA1041424A (fr)	1974-05-09	1974-05-09	Isolation des facteurs de coagulation dans des produits biologiques

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA199,415A CA1041424A (fr)	1974-05-09	1974-05-09	Isolation des facteurs de coagulation dans des produits biologiques

Publications (1)

Publication Number	Publication Date
CA1041424A true CA1041424A (fr)	1978-10-31

Family

ID=4099971

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA199,415A Expired CA1041424A (fr)	1974-05-09	1974-05-09	Isolation des facteurs de coagulation dans des produits biologiques

Country Status (1)

Country	Link
CA (1)	CA1041424A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016084097A1 (fr)	2014-11-13	2016-06-02	Hemarus Therapeutics Ltd.	Procédé de production de fibrinogène et de thrombine
CN112912725A (zh) *	2018-10-25	2021-06-04	Tl基因体科技株式会社	使用微通道对血液进行预处理以对血细胞进行分级

1974
- 1974-05-09 CA CA199,415A patent/CA1041424A/fr not_active Expired

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016084097A1 (fr)	2014-11-13	2016-06-02	Hemarus Therapeutics Ltd.	Procédé de production de fibrinogène et de thrombine
US9932388B2 (en)	2014-11-13	2018-04-03	Hemarus Therapeutics Limited	Chromatographic process for producing high purity fibrinogen and thrombin
CN112912725A (zh) *	2018-10-25	2021-06-04	Tl基因体科技株式会社	使用微通道对血液进行预处理以对血细胞进行分级

Publication	Publication Date	Title
US3920625A (en)	1975-11-18	Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
US4022758A (en)	1977-05-10	Isolation of coagulation factors I and VIII from biological material
US3842061A (en)	1974-10-15	Method for isolation of antithrombin from animal tissue materials by adsorption on sulfated carbohydrate gel
US4086222A (en)	1978-04-25	Method of isolating albumin from blood products
US3631018A (en)	1971-12-28	Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
RU1837880C (ru)	1993-08-30	Способ разделени белков крови
US4495175A (en)	1985-01-22	Preparation of highly purified human antihemophilic factor
CA1126652A (fr)	1982-06-29	Preparation d'antithrombine et procede de production
US3682881A (en)	1972-08-08	Fractionation of plasma using glycine and polyethylene glycol
US4341764A (en)	1982-07-27	Method of preparing fibronectin and antihemophilic factor
CA2024667C (fr)	2001-07-31	Procede de preparation d'un concentre de complexe de facteur viii de coagulation sanguine et de facteur de willebrnad a partir de plasma total
PL168353B1 (pl)	1996-02-29	Sposób wytwarzania zatezonego, standaryzowanego ludzkiego c z y n n i k a von Willebranda o wysokiej czystosci PL PL PL PL PL PL PL
US4404132A (en)	1983-09-13	Blood coagulation promoting product
CA2006658C (fr)	2000-03-28	Une substance anticoagulante tiree de l'urine
US4470969A (en)	1984-09-11	Process for producing a concentrate of coagulation factors VII and VIIa
CN113652414B (zh)	2023-06-30	一种高纯人凝血酶的制备方法
JPH06511018A (ja)	1994-12-08	血漿分画精製法
CA1107649A (fr)	1981-08-25	Methode de separation d'une preparation de facteur ix du plasma
CN108660126A (zh)	2018-10-16	一种冻干人凝血酶的制备工艺
US4455300A (en)	1984-06-19	Fibronectin compositions
CA1041424A (fr)	1978-10-31	Isolation des facteurs de coagulation dans des produits biologiques
EP0245875A2 (fr)	1987-11-19	Méthode pour la purification du facteur VIII
US4361510A (en)	1982-11-30	Blood coagulation promoting product
US5760183A (en)	1998-06-02	Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US5047503A (en)	1991-09-10	Thrombin-binding substance and process for its preparation